The 13th U.S. coronavirus case was confirmed Feb. 10, though CDC
officials initially cleared the patient by mistake, according to a UC
San Diego Health statement.
CDC officials said Feb. 9 that four American evacuees — assessed for
coronavirus after returning from China — tested negative for the
respiratory infection. The patients were discharged and returned to
quarantine at Marine Corps Air Station Miramar.
However, on Feb. 10, CDC officials said further testing revealed one
of the four patients actually did have the virus, now named “Covid-19,”
according to CNBC.
The individual returned to UC San Diego Health, along with another
evacuee showing possible coronavirus symptoms. Both patients are in
isolation and have minimal symptoms.
The infected evacuee left the hospital wearing a mask, and marshals
transporting the patient wore protective gear as well, according to a
Feb. 10 hospital statement cited by The San Diego Union Tribune. It is not known exactly how long the patient was at the base before officials realized the test result was actually positive.
As of 9 a.m., Feb. 11, there are 43,141 confirmed coronavirus cases and 1,018 related deaths.
https://www.beckershospitalreview.com/quality/cdc-mistakenly-clears-13th-us-coronavirus-case.html
Tuesday, February 11, 2020
Four Sanofi executives to depart in revamp
Bloomberg reports that four senior executives will be leaving Sanofi (SNY -0.1%) as a consequence of CEO Paul Hudon’s revamp.
Dominique Carouge, EVP, Business Transformation
Kathleen Tregoning, EVP, External Affairs
Dieter Weinand, EVP, Primary Care
Ameet Nathwani, M.D., EVP, Chief Medical Officer and Chief Digital Officer
https://seekingalpha.com/news/3540643-four-sanofi-executives-to-depart-bloombergInfuSystem Enters Negative Pressure Wound Therapy Market
InfuSystem
Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a
leading national health care service provider, facilitating outpatient
care for durable medical equipment (“DME”) manufacturers and health care
providers, announced today that it has entered into an agreement
whereby it will add Negative Pressure Wound Therapy (“NPWT”) to its
Integrated Therapy Service (“ITS”) platform. As part of the new
relationship, InfuSystem’s turnkey solutions will include providing the
durable medical equipment, overseeing logistics, biomedical services,
and managing third-party billing.
Richard
DiIorio, chief executive officer of InfuSystem, said, “We are pleased
to announce the addition of NPWT to the Integrated Therapy Services
platform, joining our existing therapies, oncology and pain management.
This addition results from a premier global health care services
company seeking out InfuSystem and our unique expertise in providing
clinic-to-home DME solutions. The core market to be targeted under the
new agreement is U.S. home health care, which as a subset of the broader
NPWT market, has an estimated addressable market of $600 million per
year.”
“We
are excited to collaborate with a Top-10 health care services company
on this new therapy and we look forward to a long and successful
relationship,” Mr. DiIorio continued. “As seen with past new business
wins, the nature of our ITS business involves an initial period of
on-boarding the participating facilities. We will soon begin that
on-boarding, but we do not expect to see meaningful revenue from NPWT
until the second half of this year. It should be noted that NPWT was
not part of the Company’s previously announced full-year 2020 financial
guidance. We plan to update this guidance in the coming quarters,”
concluded Mr. DiIorio.
Negative
Pressure Wound Therapy (“NPWT”) is a therapeutic technique using vacuum
dressing to promote healing of acute and chronic wounds. Examples of
acute wounds treated include those from surgery and c-sections, and
chronic wounds treated include pressure ulcers, trophic, and vascular
ulcers. The U.S. market for NPWT therapy is estimated to exceed $2
billion by 2024.
https://finance.yahoo.com/news/infusystem-enters-negative-pressure-wound-113010550.html
Caterpillar reopens most Chinese facilities
Caterpillar (CAT +1.8%) is one of today’s top gainers on the Dow Jones after the company reopened most of its facilities in China after receiving approval from the local government following the coronavirus outbreak.
None of CAT’s factories are in the worst affected
province, but the company had delayed reopening by a week after the
Lunar New Year; China accounts for ~10% of Caterpillar’s global sales.
https://seekingalpha.com/news/3540633-caterpillar-reopens-chinese-facilities
Natera teams up with Elicio in pancreatic cancer study
Cell-free DNA testing services provider Natera (NTRA -0.2%) will collaborate with Cambridge, MA-based Elicio Therapeutics on a Phase 1/2 clinical trial evaluating the latter’s therapeutic cancer vaccine candidate ELI-002 for the adjuvant treatment of patients with pancreatic ductal adenocarcinoma,
the most common type of pancreatic cancer, who have undergone
neoadjuvant chemo followed by pancreatectomy (removal of the pancreas).
Natera will use its ctDNA platform, Signatera, to
select eligible patients whose tumors harbor a mutant KRAS allele and
are at high risk for relapse because they have detectable molecular
residual disease (MRD) post-surgery. It will also use Signatera to
assess the proportion of patients achieving MRD clearance throughout the
study.
Elicio plans to file an IND for the 108-subject trial in H1.
https://seekingalpha.com/news/3540626-natera-teams-up-elicio-in-pancreatic-cancer-studyNMC Health down 11% on bearish Muddy Waters report
Ultra-thinly traded NMC Health (OTCPK:NMHLY -11%) is down, albeit on only 5,878 shares, on the heels of the latest bearish report from Muddy Waters (MW) who cites its confusing disclosures about shareholder ownership and other misstatements.
https://seekingalpha.com/news/3540627-nmc-health-down-11-on-bearish-mw-report
https://seekingalpha.com/news/3540627-nmc-health-down-11-on-bearish-mw-report
Genprex up 29% on license for diabetes gene therapy
Nano cap Genprex (GNPX +28.6%) is up on more than double normal volume in reaction to its agreement with the University of Pittsburgh for exclusive rights to a gene therapy for the potential cure of type 1 and type 2 diabetes.
The gene therapy acts by reprogramming alpha cells
in the pancreas into beta-like cells, restoring their function and
increasing insulin levels.
The company plans to pursue development partners globally.
Financial terms are not disclosed.
https://seekingalpha.com/news/3540550-genprex-up-29-on-license-for-diabetes-gene-therapy
Subscribe to:
Comments (Atom)